Ashfords’ corporate team have once again acted for BGF and Parkwalk as lead investors in the recent $20 million funding round, for exciting health tech innovation Enita - an innovative remote patient monitoring solution for people undergoing cancer treatment.
BGF and Parkwalk are well established active investors who manage a number of funds - taking minority stakes in scaling UK businesses and supporting them on their growth journeys.
They each have their own focus areas and preferred sectors, but where these interests overlap (such as in health-tech and life-sciences) they have often lead on investment rounds together.
Ashfords has supported these shareholders on many joint and individual investments over the years.
Ashfords’ corporate team are highly experienced at advising both venture capital (VC) investors and companies seeking equity funding, having advised large numbers of clients from both perspectives and supported countless investment rounds through to completion.
We worked very closely with these investors and liaised with our contacts on a daily basis whilst the round was progressing, positioning ourselves as an extension of their internal teams and helping to ensure that all parties were fully up-to-date on all key issues.
As with previous investments, our role was to liaise with the lawyers acting for the company and negotiate the investment documents to ensure that the investors’ interests were protected.
Our experience and relationship with BGF and Parkwalk, plus deep understanding of their goals and requirements, helped to bring the investment round to a smooth and timely close.
All parties, including BGF and Parkwalk and the various minority investors who also supported the round, were pleased with the outcome. We look forward to seeing Entia continue to develop its blood testing technology and improve the lives of people with cancer.